BioOutsource Launches IgG Glycosylation Tool
The assay will provide information on biosimilar comparability.
Sartorius Stedim subsidiary BioOutsource announced on July 7, 2016 that it is launching a new biosimilarity comparability tool to measure IgG glycosylation. The tool incorporates a collection of orthogonal methods, including analysis by CD16a (FcγRIIIa), surface plasmon resonance spectroscopy for ligand binding, and antibody-dependent cell-mediated cytotoxicity (ADCC) functional assays.
The tool will generate information on the molecular structure of a drug as well as its key mechanism of action, allowing scientists to accurately characterize investigational biosimilar molecules and identify glycosylation patterns.
“The structural classification and monosaccharide composition of carbohydrates attached to the constant region of therapeutic biosimilar antibodies is key to their binding,” said Daniel Galbraith, CSO at Sartorius Stedim BioOutsource, in a press release. “An accurate understanding of these glycans ensures effective selection of biosimilars that have the optimum ADCC activity to destroy tumor cells.”
Source: Sartorius Stedim BioOutsource
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
